Palforzia® peanut oral immunotherapy – update 

You may have seen recent reports that Palforzia®, a licensed peanut oral immunotherapy treatment, has been discontinued. We can confirm that this is correct and outline below what this means for people living with peanut allergy. 

The manufacturer of Palforzia®, Stallergenes Greer, has confirmed that it has made the decision to stop production worldwide. Hospitals have been advised not to start any new patients on Palforzia® after 1 April 2026. The manufacturer has stated that this decision is not related to the safety, quality or effectiveness of the treatment. 

At present, there are no other licensed immunotherapy treatment options for peanut allergy. 

If you are awaiting treatment 

If you are currently on a waiting list to start Palforzia®, your hospital should contact you directly to explain this change. In the meantime, it remains important to continue strictly avoiding peanuts, and to always carry two of your prescribed emergency medications. 

If you have been given a start date 

If you have already received a confirmed start date, hospitals have been reassured by the manufacturer that there should be sufficient supplies of Palforzia® for patients to complete treatment. If supply issues do arise during the “up-dosing” phase, your allergy team may discuss alternative approaches, such as moving to a carefully measured dose of peanut under medical supervision. 

If you are already on treatment 

If you or your child are already receiving Palforzia®, you should continue taking your current dose and follow the advice given at your most recent clinic appointment. If you have any concerns or questions, we encourage you to discuss these with your allergy team, who are best placed to advise you on your individual situation. 

We recognise that this news may be worrying and disappointing for individuals and families affected by peanut allergy, and we understand the uncertainty it may cause. While this decision is understandably upsetting, and may seem like a setback for the allergy community, we would like to reassure you that extensive research into allergy treatments is ongoing. Experts across the UK and internationally are continuing to work hard to explore and develop alternative approaches. In particular, significant progress is being made in real-food immunotherapy, with the aim of making these treatments safer, more effective and more widely available through the NHS in the future.

As a registered charity supporting people across the UK affected by serious allergies, Anaphylaxis UK remains committed to providing clear information and practical support to individuals, families, businesses and healthcare professionals. If you would find it helpful to talk through your concerns, our free helpline is available. You may also wish to connect with others who have experience of living with serious allergies through our Support Group Programme, which will be expanding later this year. 

We would also like to highlight an explainer video by Dr Helen Evans-Howells, Chair of our Clinical and Scientific Panel, which provides further clarification on what this announcement means. This can be viewed on Instagram here. 

If this news has affected you and you need support or reassurance, please do not hesitate to get in touch with us at Anaphylaxis UK.